A Study to Analyze Septal Pathology Biomarkers in Hypertrophic Cardiomyopathy

Overview

About this study

Previous work has shown that high sensitivity troponin levels are associated with degree of septal hypertrophy in hypertrophic cardiomyopathy. To further evaluate for the mechanisms of this association, we plan to reavaluate the septal pathology from myectomies in patients with HCM. Our hypothesis is that high sensitivity troponin (hs-TnT) and other biomarkers including NT-pro BNP will correlate with septal pathology in hypertrophic cardiomyopathy (HCM).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Jeffrey Geske, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions